Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies

The pathetic malignant mesothelioma (MM) is a extremely uncommon and confrontational tumor that evolves in the mesothelium layer of pleural cavities (inner lining- visceral pleura outer parietal pleura), peritoneum, pericardium, tunica vaginalis highly resistant to standard treatments. In mesothelioma, predominant pattern lesions loss genes limit tumour growth. Despite worldwide ban on manufacture supply asbestos, prevalence continues increase. Mesothelioma presents behaves variety ways, making diagnosis challenging. Most treatments available today for MM are ineffective, median life expectancy between 10 12 months. However, recent years, considerable progress has already been made understanding genetics molecular pathophysiology by addressing hippo signaling pathway. development progression related many important genetic alterations. This NF2 and/or LATS2 mutations activate transcriptional coactivator YAP. X-rays, CT scans, MRIs, PET scans used diagnose MM. treated with surgery, chemotherapy, first-line combination second-line treatment, radiation therapy, adoptive T-cell targeted cancer vaccines. Recent clinical trials investigating function surgery have led innovative approaches treatment associated effusions as well introduction medications. An interdisciplinary collaborative approach needed effective care persons who because rising intricacy treatment. article highlights key findings pathogenesis special emphasis management mesothelioma.